-
公开(公告)号：HRP20230261T1
公开(公告)日：2023-04-14
申请号：HRP20230261
申请日：2018-12-14
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： ZHENG GUOZHU , BAMBERGER MARK J , SMUKSTE INESE
-
公开(公告)号：BR112022001123A2
公开(公告)日：2022-03-15
申请号：BR112022001123
申请日：2020-07-23
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： KEEFE DENNIS , ZHENG GUOZHU , BROCCOLI VANIA
IPC: A61K45/06 , A61K31/4245 , A61P25/16 , A61P25/28
Abstract: o composto peptidomimétido (r)-2-amino-n-((s-l-(((s)-5-amino-l-(3-benzil-1,2,4,-oxadiazol-5-il)pentil)amino-3-(4-hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5-guanidinopentanamida no tratamento de doenças neurodegenerativas. a presente divulgação fornece novos métodos para tratar ou prevenir a esclerose lateral amiotrófica (als), métodos para retardar o início dos sintomas neurológicos associados à als, aumentar a sobrevivência em sujeitos afetados por als e atenuar o declínio da força muscular associada à als em um sujeito precisando do mesmo. a presente divulgação também fornece métodos para tratar ou prevenir a-sinucleinopatia ou proteinopatia tdp-43. os métodos compreendem administrar ao sujeito uma quantidade eficaz de um composto peptidomimético direcionado a mitocôndrias, tal como (r)-2-amino-n-((s)-1-(((s)-5-amino-1-(3-benzil-1,2,4-oxadiazol-5-il)pentil)amino)-3-(4-hidroxi-2,6-dimetilfenil)-1-oxopropan-2-il)-5-guanidinopentanamida, ou um sal, estereoisômero, tautômero, hidrato e/ou solvato farmaceuticamente aceitável do mesmo.
-
公开(公告)号：AU2019403856B2
公开(公告)日：2025-05-01
申请号：AU2019403856
申请日：2019-11-19
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： ZHENG GUOZHU , BAMBERGER MARK J , SMUKSTE INESE
Abstract: Disclosed are analogs of SBT-20. The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
-
公开(公告)号：RS64128B1
公开(公告)日：2023-05-31
申请号：RSP20230287
申请日：2018-12-14
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： ZHENG GUOZHU , BAMBERGER MARK J , SMUKSTE INESE
-
公开(公告)号：CA3156499A1
公开(公告)日：2021-04-08
申请号：CA3156499
申请日：2020-10-02
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： KEEFE DENNIS , ZHENG GUOZHU , ARSENJANS PAVELS
IPC: C07F7/08 , C07C50/28 , C07D201/00
Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g. Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).
-
Patent Agency Ranking
公开(公告)号：AU2018385690B2
公开(公告)日：2023-07-27
申请号：AU2018385690
申请日：2018-12-14
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： ZHENG GUOZHU , BAMBERGER MARK J , SMUKSTE INESE
Abstract: Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
-
公开(公告)号：HUE061271T2
公开(公告)日：2023-06-28
申请号：HUE18888579
申请日：2018-12-14
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： ZHENG GUOZHU , BAMBERGER MARK , SMUKSTE INESE
-
公开(公告)号：SI3723783T1
公开(公告)日：2023-04-28
申请号：SI201830867
申请日：2018-12-14
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： ZHENG GUOZHU , BAMBERGER MARK J , SMUKSTE INESE
-
公开(公告)号：AU2020358970A1
公开(公告)日：2022-04-14
申请号：AU2020358970
申请日：2020-10-02
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： KEEFE DENNIS , ZHENG GUOZHU , ARSENJANS PAVELS
IPC: C07F7/08 , C07C50/28 , C07D201/00
Abstract: The disclosure provides therapeutic compositions (
-
公开(公告)号：AU2020316449A8
公开(公告)日：2022-02-17
申请号：AU2020316449
申请日：2020-07-23
Applicant: STEALTH BIOTHERAPEUTICS INC
Inventor： BROCCOLI VANIA , KEEFE DENNIS , ZHENG GUOZHU
IPC: A61K31/4245 , A61K45/06 , A61P25/16 , A61P25/28
Abstract: The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.022 seconds)
